U.S. Markets closed

Enzolytics Inc. (ENZC)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1195+0.0045 (+3.91%)
At close: 3:59PM EDT
Sign in to post a message.
  • K
    Kalki
    Friends, I am out of $ENZC with a hefty loss. I will definitely get in again if conditions improve. Meanwhile, I wish good luck to all.
    Bullish
  • G
    GForce
    My favorite stocks under $1 are HLYK and ENZC. I love ENZC stock at this pricepoint, limited downside here. Lots of potential just have to be patient with this one. Good luck to those long with me!
    Bullish
  • C
    Casey
    Very optimistic about May. Rumors of Intel partnership. Audited fins and QB up list. Would love to see a PR updating progress on identified and patented conserved/immutable sites to get the party started. Also address the situation in India and what our role may be. We are loaded with catalysts both short and long term. All things considered, and the fact that you can get ENZC on a ridiculous discount right now, screams reversal soon. Not a bad time to get off the sidelines for those who have been timing their entry. Sleeping giants don't sleep forever.

    MM's just need to hold our beer and let it run.
    Bullish
  • m
    mikkyl
    We are on the precipice of this stock taking off! Tune out the negative voices!
    Bullish
  • J
    James
    What is target date for releasing audited financials ?
  • B
    Bob
    I'm not sure you stock sellers realize that this company leases lab space at Texas A&M. That alone is worth a 1b valuation.
  • A
    Anthony
    Time to load up! Great potential and a wonderful pipeline of products!🍻
    Bullish
  • E
    Eric
    Curious that the post premonition crowd (Rusty, TD, Frank, etc) are completely absent from the board today. Logic dictates their negativity worked and they were able to get themselves and their handlers in low, and bough up a chuck of shares today.
  • C
    Casey
    Just a quick update between meetings. My lack of posts lately isn't at all a reflection on my enthusiasm for ENZC. With everyone getting back to work I have been much busier and haven't had the time to post as frequently. The company continues to make progress and they have provided a realistic time frame for clinical trials which I absolutely love. I 100% believe that we will see multiple collaborations come to fruition on both the clinical and technical fronts in the near future. Enzolytics is a sleeping giant and is a major candidate to partner with BP and/or a buyout. No way will I sell a single share before we achieve the milestones that I set out in my strategy when we were sub-penny: NIH funding, partnerships/BO. There is no way around it.. BP needs what we have. We just have to cross a few hurdles first by satisfying EMA clinical testing standards and provide audited financials. We already have the data showing incredible efficacy and safety from previous testing at Harvard and others which will be considered by the EMA and expedite the process. Don't forget that EMA approval = FDA approval. Audited fins should be out in May followed by up listing to OTCQB.

    If you are looking for a quick flip you may want to consider other options. There are plenty of pump and dumps out there that trade on hype and momentum alone. Get in and out for a quick scalp. If you are looking for a long term investment however with potential once in a lifetime returns (I don't say this lightly as I'm aware of how "pumpy" it sounds) then you wont find a better candidate than ENZC. No promises on short term price action but fundamentally we are incredibly undervalued right now when you consider the current MC against what someone will pay for our IP through licensing deals and/or a buyout.

    Truly holding long and strong here.

    GLTA!
    Bullish
  • D
    Danny
    The quiet is a good sign! :) Shorts and MM's are not interested in this stock anymore. Supports the legitimacy of the company. Someone forgot to tell TD though.
  • D
    Don Ovan
    So for months Frank has been here pretending that he is contemplating a position in ENZC and now is in full-on basher mode having been exposed for the paid basher he is. I suggest everyone mute him. And TD. They offer nothing.
  • E
    Eric
    Seeing a double bottom in my charts, but I'm no expert. I tried to snap up a few thousand more yesterday but my limit didn't hit.
  • B
    Ben
    This is just the start of the run
    Bullish
  • P
    Paul
    For those of you tired of listening to the paid bashers on the page; I would suggest using Discord. You will find a positive amount of DD is being shared on Discord!! This is an excellent long term investment!! Don't kid yourself.. the bashers on this forum are paid to con you out of your shares!! I have a long term/bullish 3.5M ENZC share investment!!
    Bullish
  • C
    C-Money
    Anyone read IMNM's press release. They claim to have an antibody cocktail that is effective against many of the different variants. "targeting epitopes conserved across known variants" sounds awfully similar the wording and technology used from a certain company you may have heard of. Could the collaboration rumors between us and Immunome actually be true? Well I sure hope so
    Bullish
  • s
    stockpick4u
    ENZC run up imminent target 1.00+ #millionairemindset
    Bullish
  • D
    Don Ovan
    Up almost 15% today. Where is Frank (aka Rusty and TD)? Oh the humanity!
  • N
    Nick
    Monoclones are very expensive and take tons of time for clinical trials.
    read below:

    From the HuMabMouse, there have also been eight antibody drugs approved by the US FDA (Table 5). Two drugs, ipilimumab (Yervoy, Bristol-Myers Squibb, human IgG1) and nivolumab (Opdivo, Bristol-Myers Squibb, human IgG4/kappa), are used for melanoma treatment; the drugs were approved in 2011 and 2014, respectively. Ipilimumab binds to CTLA-4, an immune checkpoint inhibitor, blocking its interaction with B7 on APCs and causing cytotoxic T lymphocytes to kill cancer cells [190]. Nivolumab recognizes to PD-1, reducing inhibitory signaling to rehabilitate the immune response of tumor-specific T cells in patients [191]. Notably, nivolumab was also approved for non-small cell lung cancer treatment in 2018. Among the mAb drugs derived from the HuMabMouse, some are used for autoimmune diseases. For example, ustekinumab (Stelara, Johnson & Johnson, human IgG1/kappa) binds to cytokines, especially the p40 subunits of IL-12 and IL-23, blocking proinflammatory signaling to ease inflammation. This drug was approved for severe plaque psoriasis [17] in 2009 and for Crohn’s disease [192] in 2016.

    The VelocImmune mouse is a second generation transgenic chimeric mouse and has yielded four approved drugs (Table 5). Dupilumab (Dupixent, Sanofi and Regeneron, human IgG4) binds to IL-4 receptor and inhibits the IL-4 and IL-13 pathway, as an eczema treatment. Sarilumab (Kevzara, Sanofi and Regeneron, human IgG1) inhibits IL-6 signaling by binding to the IL-6 receptor (IL-6R), which otherwise would upregulate the release of rheumatoid arthritis-related factors from hepatocytes. The two drugs were both approved in 2017. Notably, despite having access to the XenoMouse and owning Cambridge Antibody Technology (the phage display company behind Humira), AstraZeneca paid over $120 million for a few breeding pairs of VelocImmune mice [193].
  • J
    Jude
    Cheers to whoever bought up the .15 wall
  • D
    Don Ovan
    https://twitter.com/DenverRahul/status/1386367112856293382

    Our partner is making a major announcement in India soon. Could be the catalyst that we need.